Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice

被引:122
作者
Rankin, EB
Higgins, DF
Walisser, JA
Johnson, RS
Bradfield, CA
Haase, VH
机构
[1] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Program Cell Growth & Canc, Philadelphia, PA 19104 USA
[3] Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA
[4] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA
关键词
D O I
10.1128/MCB.25.8.3163-3172.2005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Patients with germ line mutations in the VHL tumor suppressor gene are predisposed to the development of highly vascularized tumors within multiple tissues. Loss of pVHL results in constitutive activation of the transcription factors HIF-1 and HIF-2, whose relative contributions to the pathogenesis of the VHL phenotype have yet to be defined. In order to examine the role of HIF in von Hippel-Lindau (VHL)-associated vascular tumorigenesis, we utilized Cre-loxP-mediated recombination to inactivate hypoxia-inducible factor-1 alpha (Hif-1 alpha) and arylhydrocarbon receptor nuclear translocator (Arnt) genes in a VHL mouse model of cavernous liver hemangiomas and polycythemia. Deletion of Hif-1 alpha did not affect the development of vascular tumors and polycythemia, nor did it suppress the increased expression of vascular endothelial growth factor (Vegf) and erythropoietin (Epo). In contrast, phosphoglycerokinase (Pgk) expression was substantially decreased, providing evidence for target gene-dependent functional redundancy between different Hif transcription factors. Inactivation of Arnt completely suppressed the development of hemangiomas, polycythemia, and Hif-induced gene expression. Here, we demonstrate genetically that the development of VHL-associated vascular tumors in the liver depends on functional ARNT. Furthermore, we provide evidence that individual HIF transcription factors may play distinct roles in the development of specific VHL disease manifestations.
引用
收藏
页码:3163 / 3172
页数:10
相关论文
共 65 条
[1]  
Camenisch Gieri, 2002, Methods Mol Biol, V196, P117
[2]  
Chilov D, 1999, J CELL SCI, V112, P1203
[3]   Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease [J].
Clifford, SC ;
Cockman, ME ;
Smallwood, AC ;
Mole, DR ;
Woodward, ER ;
Maxwell, PH ;
Ratcliffe, PJ ;
Maher, ER .
HUMAN MOLECULAR GENETICS, 2001, 10 (10) :1029-1038
[4]   X-chromosome inactivation and the search for chromosome-wide silencers [J].
Cohen, DE ;
Lee, JT .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2002, 12 (02) :219-224
[5]  
DASILVA JL, 1990, BLOOD, V75, P577
[6]   INHIBITION OF TRANSCRIPTION ELONGATION BY THE VHL TUMOR-SUPPRESSOR PROTEIN [J].
DUAN, DR ;
PAUSE, A ;
BURGESS, WH ;
ASO, T ;
CHEN, DYT ;
GARRETT, KP ;
CONAWAY, RC ;
CONAWAY, JW ;
LINEHAN, WM ;
KLAUSNER, RD .
SCIENCE, 1995, 269 (5229) :1402-1406
[7]   Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α [J].
Flamme, I ;
Krieg, M ;
Plate, KH .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (01) :25-29
[8]   MUTATIONS OF THE VHL TUMOR-SUPPRESSOR GENE IN RENAL-CARCINOMA [J].
GNARRA, JR ;
TORY, K ;
WENG, Y ;
SCHMIDT, L ;
WEI, MH ;
LI, H ;
LATIF, F ;
LIU, S ;
CHEN, F ;
DUH, FM ;
LUBENSKY, I ;
DUAN, DR ;
FLORENCE, C ;
POZZATTI, R ;
WALTHER, MM ;
BANDER, NH ;
GROSSMAN, HB ;
BRAUCH, H ;
POMER, S ;
BROOKS, JD ;
ISAACS, WB ;
LERMAN, MI ;
ZBAR, B ;
LINEHAN, WM .
NATURE GENETICS, 1994, 7 (01) :85-90
[9]   Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice [J].
Gnarra, JR ;
Ward, JM ;
Porter, FD ;
Wagner, JR ;
Devor, DE ;
Grinberg, A ;
EmmertBuck, MR ;
Westphal, H ;
Klausner, RD ;
Linehan, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (17) :9102-9107
[10]   Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor [J].
Haase, VH ;
Glickman, JN ;
Socolovsky, M ;
Jaenisch, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1583-1588